Jiangsu Mole Bioscience obtained the approval of the Helicobacter pylori 23S rRNA gene and gyrA gene mutation test kit (fluorescence PCR method) by NMPA. This kit is the first product in China that can simultaneously detect clarithromycin and levofloxacin resistance genes.

Helicobacter pylori (Hp) is widely prevalent in the world. About 50% of the world's people have a history of Hp infection, and the infection rate of Hp in China is 40%-70%. Helicobacter pylori mainly causes diseases related to the gastrointestinal digestive system, such as dyspepsia, chronic gastritis, gastric ulcer, duodenal ulcer, atrophic gastritis, gastric MALT lymphoma and gastric cancer.

Hp infection is currently the most important and controllable risk factor for gastric cancer, and eradication of Hp is the primary preventive measure for gastric cancer. Hp eradication therapy before gastric mucosal atrophy and/or intestinal metaplasia can more effectively reduce the risk of gastric cancer. The current standard of care for eradication is quadruple therapy with two antibiotics. As the antibiotic resistance rate of Hp in China is on the rise, compared with empirical drug treatment, individualized treatment under the guidance of precise drug resistance detection can greatly improve the eradication rate.